Life-Cycle Assessment of the Breezhaler<sup>®</sup> Breath-Actuated Dry Powder Inhaler
The Breezhaler<sup>®</sup> dry powder inhaler (DPI) has a low carbon footprint compared with other inhalation therapies, consistent with the literature on other DPIs. This life-cycle assessment was conducted in France, Germany, the UK, and Japan using a “cradle-to-grave” technique to eva...
Main Authors: | Brett Fulford, Karen Mezzi, Andy Whiting, Simon Aumônier |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Sustainability |
Subjects: | |
Online Access: | https://www.mdpi.com/2071-1050/13/12/6657 |
Similar Items
-
Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial
by: Pablo Altman, et al.
Published: (2018-06-01) -
A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD
by: Miravitlles M, et al.
Published: (2016-02-01) -
Satisfaction, preference and error occurrence of three dry powder inhalers as assessed by a cohort naïve to inhaler operation
by: Man KN, et al.
Published: (2018-06-01) -
Detection of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cell in patients with Graves' ophthalmopathy
by: Hai-Bo Xue, et al.
Published: (2013-11-01) -
Lung function in adult patients with cystic fibrosis after using the eFlow<sup>® </sup>rapid for one year
by: Naehrig S, et al.
Published: (2011-02-01)